A guided tour through the antiviral drug field (Q56786373)

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Antiadenovirus activities of several classes of nucleoside and nucleotide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Acyclic/carbocyclic guanosine analogues as anti-herpesvirus agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Synthesis and antiviral activity of (Z)- and (E)-2,2-[bis(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines: second-generation methylenecyclopropane analogues of nucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic furo[2,3-d]pyrimidine nucleoside analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

New inhibitors of human cytomegalovirus (HCMV) on the horizon

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Potent, selective and cell-mediated inhibition of human herpesvirus 6 at an early stage of viral replication by the non-nucleoside compound CMV423.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Efficacy of cidofovir in a murine model of disseminated progressive vaccinia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Cidofovir in the treatment of poxvirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Design and development of oral drugs for the prophylaxis and treatment of smallpox infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Behavior of thymidylate kinase toward monophosphate metabolites and its role in the metabolism of 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-methyluracil (Clevudine) and 2',3'-didehydro-2',3'-dideoxythymidine in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Clinical activity of pleconaril in an experimentally induced coxsackievirus A21 respiratory infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Treatment of potentially life-threatening enterovirus infections with pleconaril

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Mycophenolate mofetil inhibits the development of Coxsackie B3-virus-induced myocarditis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Prospects for antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Acute Encephalitis, a Poliomyelitis-like Syndrome and Neurological Sequelae in a Hamster Model for Flavivirus Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Interferons, Interferon Inducers, and Interferon-Ribavirin in Treatment of Flavivirus-Induced Encephalitis in Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Hepatitis C therapeutics: current status and emerging strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Mechanism of action of a pestivirus antiviral compound

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Specific Inhibition of Bovine Viral Diarrhea Virus Replicase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Challenges and successes in developing new therapies for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

HCV antiviral resistance: the impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Inhibitory Effect of 2'-Substituted Nucleosides on Hepatitis C Virus Replication Correlates with Metabolic Properties in Replicon Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Discovery of alpha,gamma-diketo acids as potent selective and reversible inhibitors of hepatitis C virus NS5b RNA-dependent RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

HCV NS5b RNA-dependent RNA polymerase inhibitors: from alpha,gamma-diketoacids to 4,5-dihydroxypyrimidine- or 3-methyl-5-hydroxypyrimidinonecarboxylic acids. Design and synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Development and preliminary optimization of indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 1: Sulfonamides

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Crystallographic Identification of a Noncompetitive Inhibitor Binding Site on the Hepatitis C Virus NS5B RNA Polymerase Enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Novel nonnucleoside inhibitor of hepatitis C virus RNA-dependent RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

SARS--beginning to understand a new virus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Antivirals and antiviral strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Small molecules targeting severe acute respiratory syndrome human coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Rational design of potent sialidase-based inhibitors of influenza virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Resistant influenza A viruses in children treated with oseltamivir: descriptive study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Design, synthesis, and structural analysis of influenza neuraminidase inhibitors containing pyrrolidine cores

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Enantioselective synthesis of antiinfluenza compound A-315675.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Total synthesis of A-315675: a potent inhibitor of influenza neuraminidase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Inhibition of Respiratory Syncytial Virus Fusion by the Small Molecule VP-14637 via Specific Interactions with F Protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Short duration aerosols of JNJ 2408068 (R170591) administered prophylactically or therapeutically protect cotton rats from experimental respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Arenaviruses other than Lassa virus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Lassa fever. Effective therapy with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Viruses of the Bunya- and Togaviridae families: potential as bioterrorism agents and means of control

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Interferon alfacon-1 protects hamsters from lethal pichinde virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Defense against filoviruses used as biological weapons

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Broad-spectrum antiviral activities of neplanocin A, 3-deazaneplanocin A, and their 5'-nor derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

3-deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Viral infection and host defense

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

21 January 2018

Emerging anti-HIV drugs

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

The bicyclam AMD3100 story

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Anti-HIV activity of (-)-(2R,4R)-1- (2-hydroxymethyl-1,3-dioxolan-4-yl)-thymine against drug-resistant HIV-1 mutants and studies of its molecular mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Deoxythreosyl phosphonate nucleosides as selective anti-HIV agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Structure-activity relationship studies of a series of antiviral and antibacterial aglycon derivatives of the glycopeptide antibiotics vancomycin, eremomycin, and dechloroeremomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19

Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17460794.1.1.19